X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
ASTRAZENECA PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,285367-   
Low Rs634265-   
Sales per share (Unadj.) Rs189.6109.1-  
Earnings per share (Unadj.) Rs-0.2-27.5-  
Cash flow per share (Unadj.) Rs3.8-22.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.685.7-  
Shares outstanding (eoy) m25.00168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 174.9%   
Avg P/E ratio x-4,712.7-11.5 41,041.7%  
P/CF ratio (eoy) x249.6-13.9 -1,801.3%  
Price / Book Value ratio x14.03.7 379.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,98853,291 45.0%   
No. of employees `0001.64.3 36.3%   
Total wages/salary Rs m1,6053,345 48.0%   
Avg. sales/employee Rs Th3,040.24,290.3 70.9%   
Avg. wages/employee Rs Th1,029.2779.1 132.1%   
Avg. net profit/employee Rs Th-3.3-1,081.1 0.3%   
INCOME DATA
Net Sales Rs m4,74018,418 25.7%  
Other income Rs m92129 71.4%   
Total revenues Rs m4,83218,547 26.1%   
Gross profit Rs m-130-3,192 4.1%  
Depreciation Rs m101795 12.7%   
Interest Rs m0499 0.0%   
Profit before tax Rs m-139-4,357 3.2%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5272 1.9%   
Profit after tax Rs m-5-4,641 0.1%  
Gross profit margin %-2.7-17.3 15.8%  
Effective tax rate %-3.7-6.2 58.6%   
Net profit margin %-0.1-25.2 0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72613,490 20.2%   
Current liabilities Rs m2,4357,590 32.1%   
Net working cap to sales %6.132.0 19.2%  
Current ratio x1.11.8 63.0%  
Inventory Days Days74111 66.5%  
Debtors Days Days41124 32.9%  
Net fixed assets Rs m1,0357,863 13.2%   
Share capital Rs m5086 58.5%   
"Free" reserves Rs m9420-   
Net worth Rs m1,71614,456 11.9%   
Long term debt Rs m05,080 0.0%   
Total assets Rs m4,15627,309 15.2%  
Interest coverage xNM-7.7-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.7 169.1%   
Return on assets %-0.1-15.2 0.8%  
Return on equity %-0.3-32.1 0.9%  
Return on capital %0-19.8 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-81,572 -0.5%  
From Investments Rs m-146-483 30.2%  
From Financial Activity Rs m8624,611 18.7%  
Net Cashflow Rs m7095,700 12.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: FRESENIUS KABI ONCO.  ALKEM LABORATORIES  SUVEN LIFE  BIOCON LTD  FULFORD INDIA  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 18, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - PLETHICO PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS